Mumbai :Aurobindo Pharma Limited on Monday reported a 10.2 per cent year-on-year (YoY) drop in consolidated net profit to Rs ...

Aurobindo Pharma reported a 10.2% YoY decline in Q1 net profit to ₹824.2 crore, missing CNBC-TV18 estimates. Revenue rose 4%, ...

Aurobindo Pharma Ltd. reported a 10.3 per cent year-on-year (YoY) decline in consolidated net profit to Rs 824.2 crore in Q1 ...

Indian drugmaker Aurobindo Pharma reported a lower first-quarter profit on Monday, as expenses grew faster than revenue - stung by weak prices in the key U.S. market.

Asian markets opened higher amid positive global cues. Last checked, Japan's Nikkei 225 index was trading 0.42 per cent ...

Aurobindo Pharma on Monday reported a 10 per cent decline in its consolidated net profit to Rs 824 crore for the June quarter ...

Aurobindo Pharma's Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA), margins and net profit was also ...

Aurobindo Pharma's revenue increased by 4% year-on-year for the three months ended June, reaching Rs 7,868 crore.

Biocon and Aurobindo Pharma are identified as facing significant EPS impacts within the generics and biosimilars domain.

Stocks including Paytm, Aditya Infotech, Bosch, Laxmi India Finance, Aurobindo Pharma, DLF, Bharti Airtel, Siemens Energy and ...

Domestic equity benchmarks halted a two-day losing streak amid buying in IT, energy and auto shares on Monday, though selling ...

Aurobindo Pharma reports a 10% decline in consolidated net profit to Rs 824 crore for the June quarter, due to dwindling ...